JP5247804B2 - ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 - Google Patents

ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 Download PDF

Info

Publication number
JP5247804B2
JP5247804B2 JP2010521817A JP2010521817A JP5247804B2 JP 5247804 B2 JP5247804 B2 JP 5247804B2 JP 2010521817 A JP2010521817 A JP 2010521817A JP 2010521817 A JP2010521817 A JP 2010521817A JP 5247804 B2 JP5247804 B2 JP 5247804B2
Authority
JP
Japan
Prior art keywords
thioxo
tetrahydro
methyl
purin
mpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010521817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536849A (ja
JP2010536849A5 (https=
Inventor
ホーカン・エリクソン
ヴェルナー・ペーヴェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010536849A publication Critical patent/JP2010536849A/ja
Publication of JP2010536849A5 publication Critical patent/JP2010536849A5/ja
Application granted granted Critical
Publication of JP5247804B2 publication Critical patent/JP5247804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010521817A 2007-08-23 2008-08-22 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 Active JP5247804B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
US60/957,525 2007-08-23
US60/957,523 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013080125A Division JP2013151547A (ja) 2007-08-23 2013-04-08 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Publications (3)

Publication Number Publication Date
JP2010536849A JP2010536849A (ja) 2010-12-02
JP2010536849A5 JP2010536849A5 (https=) 2012-10-11
JP5247804B2 true JP5247804B2 (ja) 2013-07-24

Family

ID=40378392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521817A Active JP5247804B2 (ja) 2007-08-23 2008-08-22 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤
JP2013080125A Pending JP2013151547A (ja) 2007-08-23 2013-04-08 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013080125A Pending JP2013151547A (ja) 2007-08-23 2013-04-08 ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Country Status (25)

Country Link
US (6) US20090054468A1 (https=)
EP (1) EP2200616B1 (https=)
JP (2) JP5247804B2 (https=)
KR (1) KR101588464B1 (https=)
CN (4) CN103638029A (https=)
AU (1) AU2008289653B2 (https=)
BR (1) BRPI0815681A2 (https=)
CA (1) CA2698205C (https=)
CY (1) CY1113714T1 (https=)
DK (1) DK2200616T3 (https=)
EA (1) EA017510B1 (https=)
ES (1) ES2399846T3 (https=)
HR (1) HRP20130139T1 (https=)
IL (2) IL203738A (https=)
ME (1) ME01510B (https=)
MX (1) MX2010001983A (https=)
MY (1) MY155633A (https=)
NZ (1) NZ584135A (https=)
PH (1) PH12014501180A1 (https=)
PL (1) PL2200616T3 (https=)
PT (1) PT2200616E (https=)
RS (1) RS52665B (https=)
SI (1) SI2200616T1 (https=)
WO (1) WO2009025618A1 (https=)
ZA (1) ZA201000848B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013151547A (ja) * 2007-08-23 2013-08-08 Astrazeneca Ab ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN103917529B (zh) 2011-11-11 2016-08-17 辉瑞大药厂 2-硫代嘧啶酮类
JP2015512905A (ja) * 2012-03-29 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 有害動物を駆除するためのｎ−置換複素二環式化合物および誘導体ｉｉ
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
US11382918B2 (en) * 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
AU2018304508B2 (en) * 2017-07-17 2021-06-10 Astrazeneca Ab MPO inhibitors for use in medicine
CA3157260A1 (en) * 2019-10-10 2021-04-15 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
WO2021178734A1 (en) * 2020-03-05 2021-09-10 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
CA3181917A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
CN119894896A (zh) 2022-08-18 2025-04-25 阿斯利康(瑞典)有限公司 绿过氧化物酶的抑制剂
EP4580606A1 (en) * 2022-08-31 2025-07-09 Astrazeneca AB Pharmaceutical formulation
CN120265633A (zh) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses
CN121378265A (zh) * 2025-10-30 2026-01-23 乐平市康鑫医药化工有限公司 一种吡唑类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
CN101460501A (zh) * 2006-06-05 2009-06-17 阿斯利康(瑞典)有限公司 作为髓过氧化物酶抑制剂的吡咯并[3，2-d]嘧啶-4-酮衍生物
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013151547A (ja) * 2007-08-23 2013-08-08 Astrazeneca Ab ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤

Also Published As

Publication number Publication date
PL2200616T3 (pl) 2013-04-30
SI2200616T1 (sl) 2013-03-29
EP2200616A4 (en) 2010-08-25
US20110207755A1 (en) 2011-08-25
US10772890B2 (en) 2020-09-15
PH12014501180A1 (en) 2015-08-24
ZA201000848B (en) 2012-07-25
PT2200616E (pt) 2013-02-27
MY155633A (en) 2015-11-13
KR20100055434A (ko) 2010-05-26
AU2008289653B2 (en) 2012-06-28
IL240130A0 (en) 2015-09-24
MX2010001983A (es) 2010-03-10
US20090054468A1 (en) 2009-02-26
CN105687199A (zh) 2016-06-22
BRPI0815681A2 (pt) 2015-02-18
CN103638029A (zh) 2014-03-19
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
CA2698205C (en) 2016-06-21
CN101873857A (zh) 2010-10-27
US20130059870A1 (en) 2013-03-07
RS52665B (sr) 2013-06-28
WO2009025618A1 (en) 2009-02-26
HK1145141A1 (en) 2011-04-08
ES2399846T3 (es) 2013-04-03
NZ584135A (en) 2012-04-27
DK2200616T3 (da) 2013-03-04
KR101588464B1 (ko) 2016-01-25
HRP20130139T1 (hr) 2013-03-31
JP2013151547A (ja) 2013-08-08
EA017510B1 (ru) 2013-01-30
EP2200616A1 (en) 2010-06-30
CN113633641A (zh) 2021-11-12
US20190099423A1 (en) 2019-04-04
CY1113714T1 (el) 2016-06-22
AU2008289653A1 (en) 2009-02-26
US20200405724A1 (en) 2020-12-31
EP2200616B1 (en) 2012-12-26
EA201000202A1 (ru) 2010-10-29
ME01510B (me) 2014-04-20
CA2698205A1 (en) 2009-02-26
US20140221400A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
JP5247804B2 (ja) ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤
US8088951B2 (en) Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
Braun et al. The locus coeruleus neuroprotective drug vindeburnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer’s disease
US20120010178A1 (en) Methods and compounds for treatment of neurodegenerative disorders
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
US20130150346A1 (en) Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
JP2011511845A (ja) アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
US20150322049A1 (en) Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
CN111432814B (zh) 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
CN103221043A (zh) 用于治疗神经元连接发育障碍的erk抑制剂
US11103479B2 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
JP2024517653A (ja) 神経細胞プロテオームを崩壊に対して安定化して血管細胞を保護する方法
US20120094985A1 (en) Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
Melchior et al. Targeting dual specificity tyrosine-phosphorylation-regulated kinase 1A mitigates tauopathy and enhances recovery after repetitive head injury
HK1145141B (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
JP2012102069A (ja) 早漏治療剤
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130409

R150 Certificate of patent or registration of utility model

Ref document number: 5247804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160419

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250